Anavex Life Sciences Corp (AVXL)

[Hoskuld]

If the company announces 2 3-71 250 patient P3 trials - total cost probably $50m - then those take 1 year and would be a move towards commercializing something.

Strange that the missed ADL endpoint was a big deal because that is not an EMA requirement and that is totally inconsistent with CM's claim that they were asked to submit an MAA based on the known data (and ADL slight miss was very well known a year ago.)

FWIW, it is already crazy low pricing: $120m cash on a market cap of ~$300m and 2 late stage standard-of-care candidates for huge indications that are extremely underserved.